Evidence map›Paper›PMID 41143136›Full record

ArticlePathogens & immunity2025

Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025.

Kiho Tanaka, Tatenda Jimmy Blessing Chikowore, Steven G Deeks, Jacob D Estes, Ya-Chi Ho, Sizun Jiang, Ming Jie Lee, Chang Li, Albert Machinda, Mauricio Martins and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Kiho TanakaDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Tatenda Jimmy Blessing ChikoworeAfrica Health Research Institute, Durban, South Africa.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Jacob D EstesVaccine & Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon.
Ya-Chi HoDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut.
Sizun JiangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Ming Jie LeeDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Chang LiUniversity of Washington, Department of Medicine, Division of Medical Genetics, Seattle, Washington.
Albert MachindaThe Africa HIV Cure Consortium (AHCC) and CIDRZ, Zambia.
Mauricio MartinsDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida.
Patrick MdletsheCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Zaza M NdhlovuAfrica Health Research Institute, Durban, South Africa.
Ujjwal NeogiDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
Melanie M OttGladstone Institute of Virology, University of California, San Francisco, San Francisco, California.
Thomas A RasmussenDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Kavidha ReddyAfrica Health Research Institute, Durban, South Africa.
Rachel L RutishauserDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Anna Farrell-ShermanFred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington.
Caroline T TiemessenCentre for HIV and STIs, National Institutes of Communicable Diseases, a division of the National Health Laboratory Service, and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
James E VossDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California.
Cissy KityoJoint Clinical Research Centre (JCRC), Kampala, Uganda.
Sharon R LewinDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.
Joseph M McCuneHIV Frontiers, Global Health Accelerator, Gates Foundation, Seattle, Washington.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiretroviral therapy (ART) can effectively control human immunodeficiency virus (HIV) replication; however, lifelong treatment is required due to viral reservoirs, which fuel viral rebound. This necessitates curative interventions that can achieve either eradication of the reservoir or durable remission off ART. Advances in technology have fostered development of multi-omic techniques encompassing molecular tools, proteomic analyses, imaging, and artificial intelligence (AI)-driven data analysis to understand HIV reservoir biology and persistence. These have informed the investigation of therapeutic interventions such as broadly neutralizing antibodies, latency reversal, immune cell augmentation, antivirals, and gene therapy. From April 7-10, 2025, experts in the field convened at the Keystone Symposia conference, HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, to discuss novel strategies for eradication and/or durable ART-free control of HIV.

Indexed as

AfricaAnimal ModelsAntiretroviralsAntiretroviral Therapy-free ControlArtificial IntelligenceBroadly Neutralizing AntibodiesClinical TrialsCommunityCureGene TherapyHIVImagingImmune CellsLatency ReversalLMICMolecularMulti-omicsPersistenceProteomicsReservoirTherapeutics

Identifiers

PMID41143136
PMCPMC12553517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.